Ocugen (NASDAQ: OCGN) is one of 29 public companies in the “Surgical appliances & supplies” industry, but how does it contrast to its peers? We will compare Ocugen to related companies based on the strength of its risk, profitability, valuation, dividends, institutional ownership, analyst recommendations and earnings.
Insider & Institutional Ownership
56.8% of shares of all “Surgical appliances & supplies” companies are owned by institutional investors. 19.7% of Ocugen shares are owned by company insiders. Comparatively, 8.2% of shares of all “Surgical appliances & supplies” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Ocugen has a beta of 2.92, suggesting that its share price is 192% more volatile than the S&P 500. Comparatively, Ocugen’s peers have a beta of 1.11, suggesting that their average share price is 11% more volatile than the S&P 500.
This is a summary of current ratings for Ocugen and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Surgical appliances & supplies” companies have a potential upside of 2.33%. Given Ocugen’s peers higher probable upside, analysts clearly believe Ocugen has less favorable growth aspects than its peers.
Earnings & Valuation
This table compares Ocugen and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Ocugen Competitors||$1.39 billion||$142.47 million||17.58|
Ocugen’s peers have higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Ocugen and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Ocugen Company Profile
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company based in Malvern, Pennsylvania.
Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.